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20872010The study of the dissociation of the protonated molecular species [MRH]R and selected fragment
ions allowed proposals for the main fragmentation pathways of the title compounds. The main
fragments are formed by expelling a molecule of thymine, thymidine (d4T) or isopropyl. The most
striking feature of the tandem mass (MS/MS) spectra is the cleavage of CCO bonds between N-
methylpyrrole and carbonyl groups in the presence of the amidine. Electrospray ionization is proven
to be a good method for the structural characterization and identification of these kinds of
compounds. Copyright # 2009 John Wiley & Sons, Ltd.Nucleoside analogs have attracted much attention as anti-
HIV agents since they are inhibitors of HIV reverse
transcriptase (RT).1 Among them, 20,30-didehydro-20,30-
dideoxythymidine (d4T) and 30-azido-20,30-dideoxythymi-
dine (AZT) are antiviral drugs for the treatment of AIDS.2
Great efforts have been continuously made to develop and
optimize the structures of d4T and AZT. Among the major
factors which impair the efficacy of antiviral nucleoside
drugs, the phosphorylation efficiency of the drug by cellular
kinases to its active triphosphate represents a crucial step. In
this process, the monophosphorylation step is usually very
restrictive.3 Nucleoside analogues which contain a biocon-
vertible phosphate-protecting group were specifically
designed to by-pass this monophosphorylation with the
aim of improving the therapeutic characteristics of their
parent drug.4 One class of such analogues are the H-
phosphonates of d4T or AZT, which have proved to cause
less nucleoside-resistant mutants of HIV, lower cytotoxicity,
and higher anti-HIV activity.5
At the same time, distamycin is a naturally occurring
antibiotic characterized by the presence of three N-methyl-
pyrrole which binds to the DNAminor groove, preferentially
to the AT-rich sequence, and in a reversible manner. There is
a continuing effort to modify natural distamycin A to
enhance its sequence recognition and binding affinity6–9 withndence to: R. Qiao, State Laboratory of Chemical
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double-stranded (ds) DNA. Due to its DNA sequence-
recognize ability, distamycin is almost always used to deliver
cytotoxic drugs to specific sequences. Through combining
these two kinds of compounds, we would like to develop
new and potent anti-HIV prodrugs capable of inducing
damage at specific sequences. A novel series of d4T H-
phosphonate/distamycin conjugates as potent anti-HIV
drug have been synthesized and evaluated in our laboratory.
The mass spectral characteristics of similar structures have
been reported.10,11 In this paper, the fragmentation and
mechanism of these compounds were investigated using
electrospray ionization mass spectrometry (ESI-MS) com-
bined with tandem mass spectrometry (ESI-MS/MS).EXPERIMENTAL
Chemicals
All chemicals and reagents were obtained commercially and
used with further purification. Compounds 1a–d were
prepared from the coupling of previously produced polyamide
with d4T using the Atherton-Todd method; subsequently, the
nitrilewas converted into the amidine using the Pinner reaction
(Scheme 1), which was characterized by accurate mass
measurement, 1H NMR and 13C NMR spectroscopy.
Mass spectrometry
Mass spectra were acquired in positive ion mode using a
Bruker ESQUIRE-LCTM ion trap spectrometer equipped
with a gas nebulizer probe, capable of analyzing ions up to
m/z 6000. Nitrogen was used as drying gas at a flow rate of
8 L/min. The nebulizer pressure was 11.0 psi. The capillary
was typically held at 4 kV and the source temperature was
maintained at 3008C. The instrument was operated at unit-
mass resolution; calibration of m/z was performed using aCopyright # 2009 John Wiley & Sons, Ltd.
Scheme 1. Syntheses and structures of d4T H-phosphonate and distamycin con-
jugates.
ESI-MS/MS of d4T H-phosphonate and distamycin conjugates 2615standard ES-tuning-mix. Three scans were averaged for each
spectrum. The samples dissolved in methanol were ionized
by ESI and continuously infused into the ESI chamber by a
Cole-Parmer 74900 syringe pump (Cole-Parmer Instrument
Company).
RESULTS AND DISCUSSION
Given that those conjugates display similar patterns of
fragmentation, the following discussion will focus on
compound 1c as an example. The positive ionmass spectrum
of compound 1c showed the base peak at m/z 782
corresponding to the protonated molecule (Fig. 1(a)). The
main fragmentations are cleavages labeled as a, b, c,M,N and
X (Scheme 2). The most striking feature of the MS/MS
spectra of the protonated molecule [MþH]þ is the fragmentFigure 1. MS and MSn spectra of compound 1c.
Copyright # 2009 John Wiley & Sons, Ltd.ion M at m/z 656 due to the loss of thymine (Fig. 1(b)).
Meanwhile, the loss of thymine combined with the cleavage
of a path, c path and isopropyl loss led to the ions at m/z 543
(421, 299), 586 and 614, respectively. The simultaneous loss of
d4T and isopropyl attributed another striking feature of the
MS/MS spectra which is the fragment ion N/X at m/z 534.
Further, the elimination of a neutral molecule, H2O or NH3,
seemed to occur more easily because of the presence of
amidine and the enol form, such as the ions at m/z 516 and
517 corresponding to [MH-d4T-isopropyl-H2O] and [MH-
d4T-isopropyl-NH3], respectively.
To better understand the fragmentation mechanism of
these new conjugates, the ESI-MSn spectra of 1c were
acquired (Figs. 1(b)–1(d)). The fragmentation pathways of
the ion m/z 656, proposed in Scheme 3, can rationalize the
spectra obtained. After the loss of thymine from the
precursor ion m/z 782, the fragmentation pathways involved
the a cleavage (m/z 543, 421 and 299), c cleavage (m/z 586) and
the loss of isopropyl (m/z 614). Other fragmentation path-
ways showed a similar fragmentation pattern as m/z 782
including N/X, N/X-H2O cleavage, and so on. In addition,
fragmentation pathways of the ion m/z 516 are shown inScheme 2. Main fragmentation modes of d4T H-phospho-
nate and distamycin conjugates.
Rapid Commun. Mass Spectrom. 2009; 23: 2614–2618
DOI: 10.1002/rcm
Scheme 3. The fragmentation pathways of the ion m/z 656.
Scheme 4. The fragmentation pathways of the ion m/z 516.
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Table 1. MS2 and MS3 spectral data of the conjugates
Compound Precursor
Fragment ions (rel.int.)
M M/X M/a M/c a N/X/c -H2O
1d 904(70) 778(82) 736(3) 665(10) 543(14) 421(13) 299(6) 708(4) 480(16) 358(4) 568(22) 446(6)
778(10) 665(8) 543(4) 421(13) 299(7) 708(7) 480(20) 358(4) 568(12)
656(4) 480(100) 358(20) 568(11) 446(10)
1c 782(36) 656(98) 614(8) 543(4) 421(18) 299(18) 586(3) 358(39) 446(4)
656(23) 614(3) 543(4) 421(5) 299(2) 586(2) 358(20) 446(5)
516(52) 446(14)
1b 660(11) 534(100) 492(2) 421(15) 299(6) 464(4) 236(5) 324(17)
534(6) 492(5) 421(33) 299(9) 464(11) 236(33) 324(5)
394(4) 324(70)




M/X/a N/X N/X-H2O N/X-NH3 N/X/b N/X-NH3-H2O N/X/a -H2O
1d 623(10) 501(2) 379(3) 656(100) 638(54) 639(21) 569(10) 447(7) 325(23) 621(21) 525(20)
656(100) 638(60) 325(4) 621(8) 525(11)
621(20) 525(9)
1c 501(16) 379(3) 257(2) 534(81) 516(100) 517(24) 447(7) 325(14) 499(16) 403(5)
534(69) 516(100) 325(3) 499(7) 403(2)
499(100) 403(10)
1b 379(16) 257(18) 412(23) 394(49) 395(55) 325(15) 377(16) 281(4)
257(9) 412(89) 394(100) 395(35) 377(40)
377(63) 281(16)
1a 257(30) 290(19) 272(27) 273(20) 203(3)
290(7) 272(9)
Scheme 5. Possible pathway of water loss.
ESI-MS/MS of d4T H-phosphonate and distamycin conjugates 2617Scheme 4. The ions m/z 446, 324 and 202 were produced
through c cleavage from the precursor ion m/z 516. It also
gave rise to the ions m/z 403 and 114, which originated from
the CCO bond (a cleavage) cleavage. The ion m/z 499 was
observed corresponding to the loss of a neutral molecule of
NH3 due to the presence of amidine. The MS
2 and MS3
spectral data of the [MþH]þ ions, and of the most significant
fragment ions of these new conjugates, are summarized in
Table 1.
Interestingly, we presumed that the water loss may
involve two different pathways. One possible path is the
elimination of the neutral molecule H2O from the phosphor-
amidate moiety, which has been reported in some mass
spectra study of nucleoside phosphoramidate derivati-
ves.10a,12 However, owing to the presence of the amidine
and imide in these compounds studied, another reasonable
water loss may occur at the terminal of the polyamide
moiety, as shown in Scheme 5. After the elimination of the
neutral H2O from the terminal linker, it gave rise to a ring
closure to form the stable six-membered ring. Later, we will
further demonstrate this pathway of water loss through
relative experiments.Copyright # 2009 John Wiley & Sons, Ltd.Also, it is noteworthy that the ions produced from the
cleavage of CCO between N-methylpyrrole and the
carbonyl group (a pathway) showed higher relative abun-
dance in contrast to the ions obtained from cleavage of
CONH (b pathway) andNHC (c pathway). Because of the
presence of the amidine which is liable to be protonated, the
fragment with the neutral terminal O¼C¼N is formed more
easily than the fragments with C Oþ (the product of b
cleavage) and CONH2 (the product of c cleavage)
terminals. This result is consistent with the previous studies
from our laboratory.11b,11dCONCLUSIONS
In this study, the ESI-MSn data of d4T H-phosphonates and
distamycin conjugates provided abundant structural infor-
mation. The main fragmentation pathways of these new
conjugates involved the loss of thymine, thymidine (d4T),
isopropyl and sometimes combined with the elimination of
neutral molecules H2O and NH3. The cleavages in the
polyamide field mainly focus on a, b and c pathways. The a
cleavage takes place more easier than others due to theRapid Commun. Mass Spectrom. 2009; 23: 2614–2618
DOI: 10.1002/rcm
2618 J. Ding et al.presence of the amidine. With respect to the loss of water in
the course of fragmentation, we assumed two different
fragmentation pathways: water loss from the phosphorami-
date moiety and from ring closure. The ESI-MSn data of these
novel compounds, d4T H-phosphonates and distamycin
conjugates, might be valuable for structural analysis of other
related analogues.
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